Gain Therapeutics, Inc.

GANXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1819411

Concept	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$55.2K	$132.6K	$133.9K	$133.9K
Research and Development Expense	$11.5M	$8.4M	$7.2M	$2.3M
Operating Expenses	$22.3M	$17.9M	$14.0M	$3.5M
Operating Income (Loss)	-$22.3M	-$17.8M	-$13.8M	-$3.5M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$22.2M	-$17.5M	-$13.9M	-$3.6M
Income Tax Expense (Benefit)	$79.3K	$93.0K	$4.0K	$5.4K
Net Income (Loss) Attributable to Parent	-$22.3M	-$17.6M	-$13.9M	-$3.6M
Earnings Per Share, Basic	-$1.71	-$1.48	-$1.37	-$1.33

Concept	FY2024	FY2023	FY2022	FY2021
Assets	$18.6M	$24.1M	$39.0M	$9.6M
Assets, Current	$17.8M	$21.1M	$37.7M	$9.0M
Cash and Cash Equivalents, at Carrying Value	$11.8M	$7.3M	$36.9M	$7.5M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	—	$8.5K
Liabilities	$6.0M	$5.2M	$4.2M	$3.4M
Liabilities, Current	$4.9M	$4.1M	$2.6M	$2.1M
Long-term Debt	$438.5K	$567.9K	$603.4K	$694.3K
Accounts Payable, Current	$1.3M	$1.6M	$560.5K	$961.5K
Stockholders' Equity Attributable to Parent

Concept	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$18.9M	-$14.7M	-$12.4M	-$3.2M
Net Cash Provided by (Used in) Investing Activities	$10.2M	-$14.8M	-$94.2K	-$20.8K
Net Cash Provided by (Used in) Financing Activities	$12.6M	-$78.8K	$41.8M	$10.5M
Payments to Acquire Property, Plant, and Equipment	—	—	—	$20.8K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)